XML 41 R26.htm IDEA: XBRL DOCUMENT
v3.25.1

REVENUES (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Revenue from Contract with Customer [Abstract] |
Summary of Total Revenues | The following table summarizes our Total revenues:
|  | Three Months Ended March 31, 2025 |  | Three Months Ended March 31, 2024
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,474 |  |  | $ | 375 |  |  | $ | 301 |  |  | $ | 3,150 |  |  | $ | 2,315 |  |  | $ | 365 |  |  | $ | 265 |  |  | $ | 2,946 |
Descovy |  | 538 |  |  | 21 |  |  | 27 |  |  | 586 |  |  | 371 |  |  | 26 |  |  | 29 |  |  | 426 |
Genvoya |  | 305 |  |  | 40 |  |  | 19 |  |  | 364 |  |  | 332 |  |  | 49 |  |  | 21 |  |  | 403 |
Odefsey |  | 215 |  |  | 57 |  |  | 10 |  |  | 281 |  |  | 223 |  |  | 76 |  |  | 11 |  |  | 310 |
Symtuza - Revenue share(1) |  | 82 |  |  | 29 |  |  | 3 |  |  | 114 |  |  | 104 |  |  | 33 |  |  | 3 |  |  | 141 |
Other HIV(2) |  | 50 |  |  | 31 |  |  | 10 |  |  | 91 |  |  | 60 |  |  | 45 |  |  | 12 |  |  | 117 |
Total HIV |  | 3,664 |  |  | 553 |  |  | 370 |  |  | 4,587 |  |  | 3,405 |  |  | 596 |  |  | 342 |  |  | 4,342 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 166 |  |  | 80 |  |  | 99 |  |  | 346 |  |  | 248 |  |  | 79 |  |  | 78 |  |  | 405 |
Vemlidy |  | 100 |  |  | 12 |  |  | 140 |  |  | 252 |  |  | 95 |  |  | 11 |  |  | 119 |  |  | 225 |
Other Liver Disease(4) |  | 68 |  |  | 76 |  |  | 17 |  |  | 161 |  |  | 42 |  |  | 47 |  |  | 19 |  |  | 107 |
Total Liver Disease |  | 335 |  |  | 168 |  |  | 256 |  |  | 758 |  |  | 385 |  |  | 137 |  |  | 215 |  |  | 737 |
Veklury |  | 199 |  |  | 22 |  |  | 82 |  |  | 302 |  |  | 315 |  |  | 70 |  |  | 169 |  |  | 555 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 40 |  |  | 31 |  |  | 8 |  |  | 78 |  |  | 55 |  |  | 36 |  |  | 8 |  |  | 100 |
Yescarta |  | 160 |  |  | 149 |  |  | 77 |  |  | 386 |  |  | 170 |  |  | 158 |  |  | 52 |  |  | 380 |
Total Cell Therapy |  | 200 |  |  | 180 |  |  | 84 |  |  | 464 |  |  | 225 |  |  | 195 |  |  | 60 |  |  | 480 |
Trodelvy |  | 181 |  |  | 75 |  |  | 37 |  |  | 293 |  |  | 206 |  |  | 68 |  |  | 36 |  |  | 309 |
Total Oncology |  | 381 |  |  | 255 |  |  | 121 |  |  | 757 |  |  | 431 |  |  | 262 |  |  | 96 |  |  | 789 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 5 |  |  | 67 |  |  | 66 |  |  | 139 |  |  | 14 |  |  | 70 |  |  | 60 |  |  | 144 |
Other(5) |  | 47 |  |  | 9 |  |  | 14 |  |  | 70 |  |  | 59 |  |  | 9 |  |  | 12 |  |  | 80 |
Total Other |  | 52 |  |  | 76 |  |  | 81 |  |  | 209 |  |  | 73 |  |  | 79 |  |  | 71 |  |  | 224 |
Total product sales |  | 4,631 |  |  | 1,073 |  |  | 909 |  |  | 6,613 |  |  | 4,609 |  |  | 1,144 |  |  | 894 |  |  | 6,647 |
Royalty, contract and other revenues |  | 37 |  |  | 11 |  |  | 6 |  |  | 54 |  |  | 23 |  |  | 15 |  |  | 1 |  |  | 39 |
Total revenues |  | $ | 4,668 |  |  | $ | 1,084 |  |  | $ | 915 |  |  | $ | 6,667 |  |  | $ | 4,633 |  |  | $ | 1,159 |  |  | $ | 894 |  |  | $ | 6,686 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”). (2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis and Zydelig.
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods | The following table summarizes revenues recognized from performance obligations satisfied in prior years:
|  | Three Months Ended |  |
|  | March 31, |  |
(in millions) |  | 2025 |  | 2024 |  |  |  |
Revenue share with Janssen Ireland and royalties for licenses of intellectual property |  | $ | 157 |  |  | $ | 171 |  |  |  |  |
Changes in estimates |  | $ | 214 |  |  | $ | 160 |  |  |  |  |
Summary of Contract Balances | The following table summarizes our contract balances:
(in millions) |  | March 31, 2025 |  | December 31, 2024
Contract assets |  | $ | 304 |  |  | $ | 277 |
Contract liabilities(1) |  | $ | 56 |  |  | $ | 58 |
_______________________________ (1) Future revenues recognized from contract liabilities are not expected to be material in any one year.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration